Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2016

Open Access 01-05-2016 | Mini Review

Combined treatment of somatostatin analogues with pegvisomant in acromegaly

Authors: S. E. Franck, A. Muhammad, A. J. van der Lely, S. J. C. M. M. Neggers

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

Treatment of acromegaly with monotherapy long-acting somatostatin analogues (LA-SSA) as primary treatment or after neurosurgery can only achieve complete normalization of insulin-like growth factor I (IGF-I) in roughly 40 % of patients. Recently, one of the acromegaly consensus groups has recommended switching to combined treatment of LA-SSA and pegvisomant (PEGV) in patients with partial response to LA-SSAs. This combination of LA-SSA and PEGV, a growth hormone receptor antagonist, can normalize IGF-I levels in virtually all patients, requiring that the adequate dose of PEGV is used. The required PEGV dose varies significantly between individual acromegaly patients. One of the advantages of the combination therapy is that tumor size control or even tumor shrinkage can be observed in a vast majority of patients. The main side effects of the combination treatment are gastrointestinal symptoms, lipohypertrophy and transient elevated liver transaminases. In this review we provide an overview of the efficacy and safety of the combined treatment of LA-SSAs with PEGV.
Literature
1.
2.
3.
P.R. Bates, M.N. Carson, P.J. Trainer, J.A. Wass, Group UKNARS, Wide variation in surgical outcomes for acromegaly in the UK. Clin. Endocrinol. 68, 136–142 (2008)CrossRef
4.
P.U. Freda, L. Katznelson, A.J. van der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 4465–4473 (2005)CrossRefPubMed
5.
G. Amato, G. Mazziotti, M. Rotondi, S. Iorio, M. Doga, F. Sorvillo, G. Manganella, F. Di Salle, A. Giustina, C. Carella, Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin. Endocrinol. 56, 65–71 (2002)CrossRef
6.
A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed, Acromegaly Consensus G, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243–248 (2014)CrossRefPubMed
7.
P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000)CrossRefPubMed
8.
A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754–1759 (2001)CrossRefPubMed
9.
A.J. van der Lely, B.M. Biller, T. Brue, M. Buchfelder, E. Ghigo, R. Gomez, J. Hey-Hadavi, F. Lundgren, N. Rajicic, C.J. Strasburger, S.M. Webb, M. Koltowska-Haggstrom, Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589–1597 (2012)CrossRefPubMed
10.
J. Feenstra, W.W. de Herder, S.M. ten Have, A.W. van den Beld, R.A. Feelders, J.A. Janssen, A.J. van der Lely, Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365, 1644–1646 (2005)CrossRefPubMed
11.
S.J. Neggers, W.W. de Herde, J.A. Janssen, R.A. Feelder, A.J. van der Lely, Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 160, 529–533 (2009)CrossRefPubMed
12.
S.J. Neggers, S.E. Franck, F.W. de Rooij, A.H. Dallenga, R.M. Poublon, R.A. Feelders, J.A. Janssen, M. Buchfelder, L.J. Hofland, J.O. Jorgensen, A.J. van der Lely, Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 99, 3644–3652 (2014)CrossRefPubMed
13.
S.J. Neggers, M.O. van Aken, J.A. Janssen, R.A. Feelders, W.W. de Herder, A.J. van der Lely, Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92, 4598–4601 (2007)CrossRefPubMed
14.
A.J. van der Lely, I. Bernabeu, J. Cap, P. Caron, A. Colao, J. Marek, S. Neggers, P. Birman, Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol. 164, 325–333 (2011)CrossRefPubMed
15.
A.K. Annamalai, A. Webb, N. Kandasamy, M. Elkhawad, S. Moir, F. Khan, K. Maki-Petaja, E.L. Gayton, C.H. Strey, S. O’Toole, S. Ariyaratnam, D.J. Halsall, A.N. Chaudhry, L. Berman, D.J. Scoffings, N.M. Antoun, D.P. Dutka, I.B. Wilkinson, J.M. Shneerson, J.D. Pickard, H.L. Simpson, M. Gurnell, A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J. Clin. Endocrinol. Metab. 98, 1040–1050 (2013)CrossRefPubMed
16.
P.J. Caron, J.S. Bevan, S. Petersenn, D. Flanagan, A. Tabarin, G. Prevost, P. Maisonobe, A. Clermont, On behalf of the PI, Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. (2013). doi:10.​1210/​jc.​2013-3318 PubMedCentral
17.
P.J. Trainer, S. Ezzat, G.A. D’Souza, G. Layton, C.J. Strasburger, A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin. Endocrinol. 71, 549–557 (2009)CrossRef
18.
T. Laursen, J. Moller, S. Fisker, J.O. Jorgensen, J.S. Christiansen, Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. Growth Horm. IGF Res. 9, 451–457 (1999)CrossRefPubMed
19.
A. Pokrajac, J. Frystyk, A. Flyvbjerg, P.J. Trainer, Pituitary-independent effect of octreotide on IGF1 generation. Eur. J. Endocrinol. 160, 543–548 (2009)CrossRefPubMed
20.
J.O. Jorgensen, U. Feldt-Rasmussen, J. Frystyk, J.W. Chen, L.O. Kristensen, C. Hagen, H. Orskov, Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90, 5627–5631 (2005)CrossRefPubMed
21.
A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli, M. Passeri, A. Giampietro, L. Tartaglione, S. Chiloiro, M. Appetecchia, P. Gargiulo, A. Fabbri, V. Toscano, A. Pontecorvi, L. De Marinis, Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J. Exp. Clin. Cancer Res. 32, 40 (2013)CrossRefPubMedPubMedCentral
22.
I. Schreiber, M. Buchfelder, M. Droste, K. Forssmann, K. Mann, B. Saller, C.J. Strasburger, German Pegvisomant I. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 156, 75–82 (2007)CrossRefPubMed
23.
24.
A.J. van der Lely, A. Muller, J.A. Janssen, R.J. Davis, K.A. Zib, J.A. Scarlett, S.W. Lamberts, Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab. 86, 478–481 (2001)CrossRefPubMed
25.
G. Sesmilo, E. Resmini, I. Bernabeu, J. Aller, A. Soto, M. Mora, A. Pico, C. Fajardo, E. Torres, C. Alvarez-Escola, R. Garcia, C. Blanco, R. Camara, S. Gaztambide, I. Salinas, C.D. Pozo, I. Castells, C. Villabona, B. Biagetti, S.M. Webb, Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin. Endocrinol. 81, 883–890 (2014)CrossRef
26.
S.J. Neggers, W.W. de Herder, R.A. Feelders, A.J. van der Lely, Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 14, 253–258 (2011)CrossRefPubMedPubMedCentral
27.
I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89–95 (2008)CrossRefPubMed
28.
I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)CrossRefPubMed
29.
E. Kuhn, L. Maione, A. Bouchachi, M. Roziere, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173, 693–702 (2015)CrossRefPubMedPubMedCentral
30.
S.C. Hua, Y.H. Yan, T.C. Chang, Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur. J. Endocrinol. 155, 831–837 (2006)CrossRefPubMed
31.
S.J. Neggers, M.O. van Aken, W.W. de Herder, R.A. Feelders, J.A. Janssen, X. Badia, S.M. Webb, A.J. van der Lely, Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93, 3853–3859 (2008)CrossRefPubMed
32.
M. Madsen, P.L. Poulsen, H. Orskov, N. Moller, J.O. Jorgensen, Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J. Clin. Endocrinol. Metab. 96, 2405–2413 (2011)CrossRefPubMed
33.
S.J. Neggers, J.J. Kopchick, J.O. Jorgensen, A.J. van der Lely, Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur. J. Endocrinol. 164, 11–16 (2011)CrossRefPubMed
34.
K.C. Leung, N. Doyle, M. Ballesteros, M.J. Waters, K.K. Ho, Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712–4720 (2000)PubMed
35.
K.Z. Rubeck, M. Madsen, C.M. Andreasen, S. Fisker, J. Frystyk, J.O. Jorgensen, Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur. J. Endocrinol. 163, 717–726 (2010)CrossRefPubMed
36.
D.R. Rose, D.R. Clemmons, Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm. IGF Res. 12, 418–424 (2002)CrossRefPubMed
37.
W.M. Drake, S.V. Rowles, M.E. Roberts, F.K. Fode, G.M. Besser, J.P. Monson, P.J. Trainer, Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol. 149, 521–527 (2003)CrossRefPubMed
38.
A.L. Barkan, P. Burman, D.R. Clemmons, W.M. Drake, R.F. Gagel, P.E. Harris, P.J. Trainer, A.J. van der Lely, M.L. Vance, Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J. Clin. Endocrinol. Metab. 90, 5684–5691 (2005)CrossRefPubMed
39.
R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, J.O. Jorgensen, The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J. Clin. Endocrinol. Metab. 92, 1724–1728 (2007)CrossRefPubMed
40.
C.E. Higham, S. Rowles, D. Russell-Jones, A.M. Umpleby, P.J. Trainer, Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 2459–2463 (2009)CrossRefPubMed
41.
C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169, 99–108 (2013)CrossRefPubMed
42.
A.J. Krentz, P.J. Boyle, L.M. Macdonald, D.S. Schade, Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 43, 24–31 (1994)CrossRefPubMed
43.
M.E. Presti, F.R. Burton, M.L. Niehoff, J. Rioux, P.J. Garvin, Effect of octreotide on stimulated insulin release from pancreatic tissue slices. Pancreas 16, 141–147 (1998)CrossRefPubMed
44.
P.J. Caron, J.S. Bevan, S. Petersenn, D. Flanagan, A. Tabarin, G. Prevost, P. Maisonobe, A. Clermont, Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99, 1282–1290 (2014)CrossRefPubMedPubMedCentral
45.
M. Buchfelder, S. Schlaffer, M. Droste, K. Mann, B. Saller, K. Brubach, G.K. Stalla, C.J. Strasburger, The German ACROSTUDY: past and present. Eur. J. Endocrinol. 161(Suppl 1), S3–S10 (2009)CrossRefPubMed
46.
S.J. Neggers, N.R. Biermasz, A.J. van der Lely, What is active acromegaly and which parameters do we have? Clin. Endocrinol. 76, 609–614 (2012)CrossRef
47.
M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller, K. Brubach, G.K. Stalla, M. Bidlingmaier, C.J. Strasburger, Investigators of German Pegvisomant Observational S. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol. 161, 27–35 (2009)CrossRefPubMed
48.
M. Marazuela, A.E. Paniagua, M.D. Gahete, T. Lucas, C. Alvarez-Escola, R. Manzanares, J. Cameselle-Teijeiro, M. Luque-Ramirez, R.M. Luque, E. Fernandez-Rodriguez, J.P. Castano, I. Bernabeu, Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J. Clin. Endocrinol. Metab. 96, E251–E259 (2011)CrossRefPubMed
49.
P.U. Freda, M.B. Gordon, N. Kelepouris, P. Jonsson, M. Koltowska-Haggstrom, A.J. van der Lely, Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from acrostudy. Endocr. Pract. (2014). doi:10.​4158/​EP14330.​OR
50.
L.F. Grasso, R.S. Auriemma, R. Pivonello, A. Colao, Adverse events associated with somatostatin analogs in acromegaly. Expert. Opin. Drug Saf. 14, 1213–1226 (2015)CrossRefPubMed
51.
V.S. Bonert, L. Kennedy, S. Petersenn, A. Barkan, J. Carmichael, S. Melmed, Lipodystrophy in patients with acromegaly receiving pegvisomant. J. Clin. Endocrinol. Metab. 93, 3515–3518 (2008)CrossRefPubMed
52.
M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N.G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, F.F. Casanueva, I. Bernabeu, Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur. J. Endocrinol. 160, 535–542 (2009)CrossRefPubMed
53.
B. Lembcke, W. Creutzfeldt, S. Schleser, R. Ebert, C. Shaw, I. Koop, Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36, 108–124 (1987)CrossRefPubMed
54.
A. Moschetta, M.F. Stolk, J.F. Rehfeld, P. Portincasa, P.H. Slee, H.P. Koppeschaar, K.J. Van Erpecum, G.P. Vanberge-Henegouwen, Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment. Pharmacol. Ther. 15, 181–185 (2001)CrossRefPubMed
55.
Y.F. Shi, X.F. Zhu, A.G. Harris, J.X. Zhang, Q. Dai, Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J. Clin. Endocrinol. Metab. 76, 32–37 (1993)PubMed
56.
H. Biering, B. Saller, J. Bauditz, M. Pirlich, B. Rudolph, A. Johne, M. Buchfelder, K. Mann, M. Droste, I. Schreiber, H. Lochs, C.J. Strasburger, German pegvisomant i. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur. J. Endocrinol. 154, 213–220 (2006)CrossRefPubMed
57.
A. Soto Moreno, R. Guerrero Vazquez, E. Venegas Moreno, S. Palma Milla, J.P. Castano, Cerro A. Leal, Self-limited acute hepatotoxicity caused by pegvisomant. Pituitary 14, 371–376 (2011)CrossRefPubMed
58.
I. Bernabeu, M. Marazuela, T. Lucas, L. Loidi, C. Alvarez-Escola, M. Luque-Ramirez, E. Fernandez-Rodriguez, A.E. Paniagua, C. Quinteiro, F.F. Casanueva, Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J. Clin. Endocrinol. Metab. 95, 2147–2154 (2010)CrossRefPubMed
Metadata
Title
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Authors
S. E. Franck
A. Muhammad
A. J. van der Lely
S. J. C. M. M. Neggers
Publication date
01-05-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0810-8

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue

Original Article

Effect of reducing iodine excess on children’s goiter prevalence in areas with high iodine in drinking water

Original Article

Lithium prevents rat steroid-related osteonecrosis of the femoral head by β-catenin activation

Original Article

Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome

Endocrine Methods and Techniques

Flavor perception test: evaluation in patients with Kallmann syndrome

Original Article

A meta-analysis-derived proposal for a clinical, ultrasonographic, and cytological scoring system to evaluate thyroid nodules: the “CUT” score

Erratum

Erratum to: Selenium supplementation and the risk of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits